Industry Satellite Symposia
Switch To Module
ESMO Congress 2021 - Conference Calendar
On-demand Educational sessions
On-demand Special Symposia
On-demand Multidisciplinary sessions
On-demand ePosters
Industry Satellite Symposia
Digital Evaluations
Everything
Everything
Session Title
Session Number
Presentation Title
Presentation Number
Author
Presenter
Chair
Filter By
Day
Select All
Deselect All
Fri, 17.09.2021
12
Sat, 18.09.2021
11
Sun, 19.09.2021
12
Mon, 20.09.2021
11
Tue, 21.09.2021
11
Room
Select All
Deselect All
Channel 3
14
Channel 4
15
Channel 5
13
Channel 6
15
Session Type
Select All
Deselect All
Industry Satellite Symposium
57
Presentation Type
Select All
Deselect All
Invited Speaker
57
Presentation Topic
Select All
Deselect All
General interest
57
Cancel
Clear
Search
Advanced Search
Sign in
Scheduled sessions
On-demand Educational sessions
On-demand Special Symposia
On-demand Multidisciplinary sessions
On-demand ePosters
Industry Satellite Symposia
Final Programme PDF
Browsing Over 57 Sessions
Sort By
Session Number
Upcoming First
Relevance
Session Number
Session Datetime
MSD - Implementation of Immunotherapy in the First-Line Treatment of Esophageal, Gastroesophageal Junction and Gastric Cancers
(ID 113)
Time
08:45 - 10:15
Jazz Pharmaceuticals - Insight beyond Phase 3: does real-world evidence impact how we treat high-risk AML*? *High-risk AML defined as therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC)
(ID 147)
Time
08:45 - 09:45
AstraZeneca - Re-evaluating the role of gBRCA in breast cancer
(ID 104)
Time
10:30 - 12:00
Ipsen - Spotlight on emerging therapies: Multidisciplinary discussions (advanced RCC, HCC and DTC)
(ID 138)
Time
10:30 - 12:00
BeiGene - A New Breath in Lung Cancer
(ID 128)
Time
10:30 - 12:00
Daiichi Sankyo - Advances in Antibody Drug Conjugates in Solid Tumors: Current Treatments and Emerging Therapies
(ID 118)
Time
18:45 - 20:15
Deciphera Pharmaceuticals - Changing the paradigm in the management of advanced GIST: Current treatment landscape and new horizon
(ID 153)
Time
10:30 - 12:00
Merck - Current and future treatments for head and neck cancer
(ID 109)
Time
18:45 - 20:15
Bristol Myers Squibb - I-O Revolution: New Perspectives in the Treatment of Thoracic Cancers
(ID 143)
Time
18:45 - 20:15
Servier - The clinical value of mIDH1 inhibition in cholangiocarcinoma
(ID 100)
Time
08:45 - 10:15
Incyte - Making Precision Medicine a Reality for Patients with Cholangiocarcinoma
(ID 133)
Time
18:45 - 19:58
AbbVie, Inc. - A Novel Approach to Targeting c-Met in Lung Cancer
(ID 124)
Time
08:45 - 10:15